Australian regenerative medicine company Orthocell (ASX:OCC) has announced it has completed the first stage of the Remplir US 510(k) market authorisation nerve repair study. …
Orthocell completes all nerve repair surgeries in Remplir US market authorisation study
March 25, 2024 Australian Biotech
Latest Video
New Stories
-
New partnership expands access to care for Australians with rare cancers
May 19, 2026 - - Latest News -
Sandoz urges faster access as government signals biosimilar consultation
May 19, 2026 - - Latest News -
Perth hosts AusMedtech conference as industry focuses on innovation and commercialisation
May 19, 2026 - - Latest News -
Government sidesteps committee call on CGMs, insulin pumps and GLP‑1 access
May 18, 2026 - - Latest News -
Budget papers signal the work that has already been done on reform proposals
May 18, 2026 - - Latest News -
If the demand is to pay for reform, are these reforms really worth paying for?
May 18, 2026 - - Latest News -
The 'Dispatched' Week in Review' Podcast - 15 May
May 15, 2026 - - Podcast